drugset / Trial / NCT06349733
A Dosage-dependent Manner of Botulinum Toxin Type A on the Prevention of Postoperative Scars of Various Anatomic Regions of the Body
RandomizedParallel-groupQuadruple-blindPrevention
Summary
Each year, millions of burn, trauma, or surgical patients worldwide suffer from scarring that severely affects their quality of life and social functioning. In order to prevent and treat diseases related to abnormal scar hyperplasia, clinicians and researchers have adopted various methods, such as scar grinding, surgical resection, drug injection in scar tissue, cryotherapy, laser and so on. However, these methods can not effectively inhibit the abnormal proliferation of scars and improve the adverse effects of existing scars on patients. To date, there is no accepted gold standard for the effective treatment and improvement of abnormal scar tissue.
Timeline
- Start
- 2023-03-23
- Primary completion
- 2023-10-01
- Completion
- 2024-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 1 iu | Other |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 2.5 iu | Other |
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 5 iu | Other |
Indications
No indication recorded.